# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
B. Riley Securities analyst Kalpit Patel maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and lowers the price targe...
Needham analyst Serge Belanger maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and maintains $30 price target.
HC Wainwright & Co. analyst Douglas Tsao reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Buy and maintains $37 pri...
Wedbush analyst Laura Chico maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from...
Needham analyst Serge Belanger reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Buy and maintains $30 price target.
Viridian Therapeutics (NASDAQ:VRDN) reported quarterly losses of $(1.35) per share which missed the analyst consensus estimate ...
Viridian Therapeutics shares are trading lower by 5.9% Thursday morning. The company announced pricing of an underwritten publi...